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background:  Pathologic stressors disrupt cellular homeostasis and cause various diseases, mediated by stress-responsive epigenetic 
gene regulatory mechanism. Glycelaldehyde-3-phosphate dehydrogenase (GAPDH) is a classic cytosolic glycolytic enzyme, but has been 
shown to translocate to the nucleus under stress conditions, regulating histone acetyl transferase (HAT) and inducing cell death in neurons. 
We tested the hypothesis that such nuclear GAPDH signal plays a role in the cardiac stress response.
Methods and results:  In cultured rat neonatal cardiac myocytes, endothelin-1 (0.05 μM) elicited nuclear translocation of GAPDH and 
activation of p300 HAT, which were followed by activation of myocyte enhancer factor 2 (MEF2) and up-regulation of brain natriuretic 
peptide, associated with myocyte hypertrophy. Inhibition of GAPDH nuclear signaling pathway, either by introducing a dominant negative 
GAPDH mutant (K227A) using adenovirus or pharmacologically using a novel small molecule antagonist (named RR) selective to 
GAPDH nuclear, but not glycolytic function, abrogates virtually p300-HAT and MEF2 activation, ameliorating myocyte hypertrophy. In 
an in vivo mouse model for cardiac hypertrophy remodeling induced by transverse aorta constriction (TAC), we also identified nuclear 
translocation of GAPDH and consequent activation of p300 HAT. Blockade of nuclear GAPDH signal by treatment with RR (0.25 mg/kg/day 
intraperitoneally) inhibited p300 HAT activation and ameliorated cardiac hypertrophy remodeling induced by TAC for 10 days. Importantly, 
RR treatment to established cardiac hypertrophy inhibited the further progression of remodeling.
conclusion:  These results indicate that nuclear GAPDH signal activates cardiac hypertrophy via p300-HAT activation and suggest that 
blockade of this cascade with a small molecule could be a potential new therapeutic approach for cardiac hypertrophy.
